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ORIGINAL REPORT
Association between statins and infections among patients with
diabetes: a cohort and prescription sequence symmetry analysis
Koen B. Pouwels*, Niken N. Widyakusuma, Jens H. J. Bos and Eelko Hak
Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, the Netherlands
ABSTRACT
Purpose A previous meta-analysis of randomized trials did not conﬁrm ﬁndings from observational studies that suggested that statins
reduce the risk of infection. However, animal experiments indicate that statins may be more effective in reducing the risk and/or the severity
of infection among patients with diabetes. Hence, we evaluated the effect of statins on antibiotic prescriptions (a proxy for infections) among
patients with drug-treated type 2 diabetes using two confounding-reducing observational designs.
Methods We conducted a prescription sequence symmetry analysis and a cohort study using the IADB.nl pharmacy prescription database.
For the prescription sequence symmetry analysis, a sequence ratio was calculated. The matched cohort study, comparing the time to ﬁrst
antibiotic prescription between periods that statins are initiated and non-use periods, was analyzed using stratiﬁed Cox regression.
Results Prescription sequence symmetry analysis of 4684 patients with drug-treated type 2 diabetes resulted in an adjusted sequence ratio
of 0.86 (95% conﬁdence interval [CI]: 0.81 to 0.91). Corresponding ﬁgures for the cohort analysis comparing 9852 statin-initiation with
4928 non-use periods showed similar results (adjusted hazard ratio: 0.88, 95%CI: 0.83 to 0.95).
Conclusions These ﬁndings suggest that statins are associated with a reduced risk of infections among patients with drug-treated type 2
diabetes. © 2016 The Authors. Pharmacoepidemiology and Drug Safety Published by John Wiley & Sons Ltd.
key words—hydroxymethylglutaryl-CoA reductase inhibitors; cohort studies; antibiotics; Diabetes mellitus; infection; prescription
sequence symmetry analysis; pharmacoepidemiology
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INTRODUCTION
Evidence from several observational studies suggest
that statins reduce the severity and risk of various infec-
tions, including sepsis, pneumonia, hospital-acquired
infections, community-acquired infections, inﬂuenza,
bacteremia, and urinary tract infections.1–4 However,
a meta-analysis of data from large randomized statin
trials did not show a reduced risk of infections among
the treated group.5 Unmeasured confounding may
explain the discrepancy between randomized and
non-randomized studies.6,7
On the other hand, all of the randomized trials
included in the meta-analysis were primarily designed
to evaluate the effect of statins on cardiovascular
outcomes; hence, the risk of infection could be mea-
sured only post hoc. The huge variation in the inci-
dence of infections among the different trials5
suggests that the validity of the reported infectious
outcomes among the included trials may have differed.
Even when statins do not have a beneﬁcial inﬂuence
on the risk of infections in the general population at low
risk for infections, it is still possible that statins lower this
risk in certain high-risk subgroups, such as patients with
diabetes.7,8 Diabetes is associated with an increased for-
mation of bioﬁlms by different bacteria and fungi.9–11
Formation of such bioﬁlms hinders the clearance of these
pathogens by the immune system and thus increases the
likelihood that antimicrobial agents are administered to
treat an infection. A recent case–control study found that
diabetes strongly increases the risk of bioﬁlm-forming
Candida bloodstream infection but was not a risk factor
for non-bioﬁlm-forming Candida bloodstream infec-
tions.11 Hence, drugs reducing the likelihood of bioﬁlm
formation may be more effective among patients with
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diabetes than patients without diabetes. Simvastatin pos-
sesses pronounced antimicrobial activity against Staphy-
lococcus aureus bioﬁlms,12 suggesting that statins may
reduce the risk of infection or reduce the need to use an-
tibiotic treatment among patients with diabetes.
Statins are also known to reduce the amount of
membrane-associated or activated Rac1,13–15 a Rho
GTPase involved in bacterial invasion.16–19 This activity
against Rac1 may explain the observation in pre-clinical
studies that statins reduce bacterial invasion.20,21 Several
studies indicate that diabetes is associated with increased
Rac1 activation,22,23 suggesting that statins should be
particularly effective among patients with diabetes.
Among patients without diabetes, the potentially smaller
beneﬁts may be outweighed by the increased risk of inci-
dent diabetes among patients using statins.24
Some observational studies with conventional cohort
and case–control designs suggest that statins may
reduce the risk of infection among patients with drug-
treated type 2 diabetes, but unmeasured confounding
could not be ruled out.25–29 Hence, we aimed to evalu-
ate whether statins reduce the risk of receiving ﬁrst
antibiotic prescriptions (as a proxy for infections)
among patients with drug-treated type 2 diabetes using
two observational studies that are designed to address
confounding in different ways: a prescription sequence
symmetry analysis (PSSA) and a matched cohort
study. In secondary analysis, we evaluated whether
the effect among patients without drug-treated diabetes
would be less pronounced.
MATERIALS AND METHODS
This study was performed with the University of
Groningen IADB.nl pharmacy prescription database,
which contains prescription data collected from com-
munity pharmacies and covers an estimated population
of 600000 persons in the Netherlands (www.iadb.nl).
Age, gender, and prescription rates among the database
population have been found to be representative for the
Netherlands as a whole.30 Each participant has a
unique anonymous identiﬁer; date of birth and gender
are known. The medication records of each patient
are virtually complete, except for over the counter
drugs and medication dispensed during hospitaliza-
tion.30 Data between January 1999 and December
2012 were used for the analyses.
Prescription sequence symmetry analysis
We ﬁrst applied a PSSA, a case-only design that has
powerful properties to control for genetic and other
time invariant confounding.31–35 Because only
patients that have an indication to initiate the treatment
of interest are included and all of them experience the
outcome of interest close to the date of treatment initi-
ation, confounding between study subjects is mini-
mized. To be able to apply this design, individuals
initiating both statin treatment (ATC codes C10AA
and C10B) and antibiotic treatment (ATC code J01)
between January 1999 and December 2012 were se-
lected from the IADB.nl database. Patients who initi-
ated antibiotics and statins on the same date were
excluded. Patients were only included in the study
when they were present in the database for a least
13months before initiation of statin or antibiotic treat-
ment (whichever came ﬁrst). Furthermore, we required
patients to be 45–80years old at the date of statin ini-
tiation, an age range that agrees with the previously
mentioned meta-analysis.5 Moreover, the majority of
statin initiators will fall in this age category. Patients
with drug-treated type 2 diabetes were selected by
the use of two prescriptions of non-insulin blood-
glucose lowering drugs (ATC code A10B) within
12months before the date of statin initiation. We
excluded patients on insulin monotherapy, because
the majority of those patients have type 1 diabetes.
This implies that approximately 6% of type 2 diabetes
patients that are only treated with insulin are excluded
from the current study.36 As we restricted our popula-
tion to 45–80years old, misclassiﬁcation because of
metformin use for polycystic ovary syndrome is not
likely an important source of bias. Subsequently, the
PSSA was performed to evaluate whether antibiotics
were more initiated in the 13months prior statin initia-
tion than the 13months after statin initiation. By divid-
ing the number of patients that ﬁrst initiate statins and
then antibiotics by the number of patients that ﬁrst ini-
tiate antibiotics before initiating statin treatment the
sequence ratio (SR) is obtained. We adjusted for trends
in prescribing by adjusting the SR by dividing by the
null ratio.31–34 We estimated 95% conﬁdence intervals
(CIs) using a normal approximation to the binomial
distribution.
Matched cohort design
Second, we applied a matched cohort design. We used
the same inclusion and exclusion criteria as in the
PSSA. However, instead of selecting only patients ini-
tiating statins and antibiotics, periods in which patients
initiated statins were 1:1 matched to non-use periods
based on age (±5years), gender, calendar date
(±60days), and duration of diabetes in years.
Matching was used to be able to determine a start of
follow-up (index date) for non-use periods among
k. b. pouwels et al.
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comparable patients. Patients were considered statin
initiators if they received a ﬁrst statin prescription after
a period of at least a year without any statin prescrip-
tion. Non-use periods were deﬁned as periods where
a patient did not receive a statin prescription in the
12months before or 13months after the index date.
We compared statin initiation periods with non-use
period instead of users versus non-users to gain more
statistical power.37,38 Consequently, some patients
contribute to both use and non-use periods, which
reduces confounding compared with evaluations
where never-users are used as controls. Follow-up
was started at the date of statin initiation (index date
for controls) and stopped at 13months, similar to the
PSSA. When the survival analysis follow-up period
matches the symmetry window and there is no loss
to follow-up, the hazard ratio and sequence ratio
should approximate each other.39
Stratiﬁed (to take into account matching) Cox pro-
portional hazard regression was used to evaluate the
risk of receiving antibiotic treatment during periods
that statins are used compared with non-use periods.
The following variables were considered as potential
(proxies for) risk factors for receiving antibiotic treat-
ment: cardiovascular drugs,40 antithrombotic agents,
systemic corticosteroids, immunosuppressants, antivi-
rals, antineoplastics, and drugs for obstructive airway
diseases, acid-suppresive drugs, number of antibiotic
prescriptions in the previous year, and duration of dia-
betes. All potential risk factors were included in the
ﬁnal multivariate model. We tested for effect modiﬁca-
tion by age by assessing the signiﬁcance of an interac-
tion between statin use and age. Robust variance
estimators were used to estimate conservative 95%
CI, to account for the fact that some patients contrib-
uted more than one episode.38 We graphically assessed
whether the proportional hazard assumption was met.
Statistical analyses were performed using R version
3.0.2. We reported our study in line with a previous
paper that pointed out eight important items to enable
adequate assessment of the likelihood that a study is
affected by unmeasured or residual confounding.41
Sensitivity analyses
It has been hypothesized that although statins seem to
have no beneﬁcial inﬂuence on the risk of infections in
the general population,5 statins might lower the risk in
certain subgroups.7 Therefore, in secondary analysis,
we evaluated whether the sequence ratio among
patients not treated with any blood-glucose lowering
drugs (ATC code A10)—including patients without
diabetes and potentially some diabetic patients that
are not treated with glucose-lowering drugs—prior
statin initiation would be more close to 1, indicating
no effect.
We also performed two sensitivity analyses using
the PSSA. In the ﬁrst sensitivity analysis, we evaluated
whether associations were different for different
groups of antibiotics among patients with drug-treated
type 2 diabetes. We estimated the adjusted sequence
ratios for the following groups of antibiotics: tetracy-
cline, beta lactam penicillins, sulphonamides and tri-
methoprim, macrolides, quinolone, and nitrofurantoin.
The PSSA is vulnerable to factors that are both asso-
ciated with antibiotic use and the timing since statin
use. Therefore, we estimated the adjusted sequence
ratio using a maximum time-span of 30days between
ﬁrst statin and antibiotic prescriptions, thereby limiting
the inﬂuence of factors that may change over time.
RESULTS
In total, 4684 patients with drug-treated type 2 diabe-
tes initiated antibiotics within 13months of statin initi-
ation. Patients were on average 63years old (SD 9),
53% was female, 69% had recorded use of cardiovas-
cular drugs, 23% recorded use of antithrombotic agent,
6% recorded use of systemic corticosteroids, and 15%
recorded use of drugs for obstructive airway diseases.
Immunosuppressants, antivirals, and antineoplastics
were used by less than 1% of the patients.
Of all incident statin users, 2513 patients received
their ﬁrst antibiotic prescription before starting statin
therapy and 2132 patients started their antibiotic course
after initiating statin therapy. These numbers corre-
spond to a crude SR of 0.85 (95%CI 0.80–0.90). After
adjusting for trends in prescribing an adjusted sequence
ratio (aSR) of 0.86 (95%CI 0.81–0.91) was obtained
(Table 1).
When the maximum time-span between both pre-
scriptions was reduced to 30days the aSR slightly
decreased (aSR 0.78, 95%CI 0.64–0.94). Excluding
that period from the main analysis resulted in an al-
most identical sequence ratio (aSR 0.86, 95%CI
0.81–0.92).
The effect was fairly consistent across different
types of antibiotics (Table 1). Nitrofurantoin is an
antibiotic almost solely used to treat urinary tract
infections and may therefore serve as a valid proxy
for urinary tract infections.32,34 The point estimate
for nitrofurantoin was similar as the estimate for all
antibiotics (aSR 0.85 vs 0.86).
In secondary analysis, the association between
statin initiation and receiving antibiotic prescriptions
was much weaker among patients not treated with
effect statins on infections among diabetics
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blood-glucose lowering drugs (aSR 0.96, 95%CI 0.93
to 0.99).
For the survival analysis, 9852 patients with drug-
treated type 2 diabetes that initiated statin therapy
and met inclusion criteria were identiﬁed. Subse-
quently, 4928 patients with drug-treated type 2 diabe-
tes with non-use episodes could be matched to the
exposed periods. During episodes of statin initiation
patients were slightly younger and had a shorter
duration of diabetes (Table 2). During follow-up
3000 ﬁrst antibiotic prescriptions were observed
among the participants. Periods of statin use were
associated with a reduced hazard of antibiotic prescrip-
tions compared with non-use periods (crude HR 0.85,
95%CI 0.79–0.92). Adjusting for all potential
confounders resulted in a similar hazard ratio (adjusted
HR [aHR] 0.88, 95%CI 0.83–0.95). Other cardiovas-
cular medication and antithrombotic agents were both
not associated with a reduction in antibiotic prescrip-
tions in the multivariate cox model (aHR 1.03, 95%
0.92–1.15 and aHR 1.03, 95%CI 0.90–1.17,
respectively). The effect of statin initiation was not
signiﬁcantly modiﬁed by age (p=0.53). When the
patient population was restricted to patients classiﬁed
as drug-treated diabetes patients at least one year prior
statin initiation, similar results were obtained for statin
initiation (aHR 0.91, 95%CI 0.85–0.99). Graphical
assessment of the proportional hazard assumption
showed that this assumption was met for all covariates.
DISCUSSION
Statin initiation was associated with a decreased risk of
receiving antibiotic prescriptions among patients with
drug-treated type 2 diabetes. Both the PSSA, the unad-
justed and adjusted survival analyses gave almost
identical results. The similarity between the different
designs suggests that the obtained results are not likely
because of confounding.
It may seem surprising that the results of the
adjusted and unadjusted survival analyses were almost
identical. However, non-use and use periods were very
similar with regard to measured risk factors for infec-
tions, which can be partly explained by the fact that
patients could contribute to both the use and non-use
periods. Moreover, in a previous study that evaluated
the effect of statins on the occurrence of pneumonia
in patients with diabetes, the crude effect estimate
did hardly change after adjustment for a large set of
potential confounders.25 In that study, patients were
matched by practice, which may actually amplify the
bias induced by unmeasured confounders, so-called
ampliﬁcation bias.42 Moreover, in that study, prevalent
users were compared with never users, which may
further bias the results.43,44
Hence, our study is relevant, as it is the ﬁrst study
that evaluated whether a protective effect against
infections among patients with type 2 diabetes is likely
because of time-invariant unmeasured confounding.
To date, there are no randomized controlled trials
available evaluating the effect of statins on the occur-
rence of infections among patients with drug-treated
Table 1. Time-trend adjusted sequence ratios for the association between statin initiation and antibiotic treatment initiation
Antibiotic (ATC code)
Number of patients initiating antibiotic treatment within





Any (J01) 4684 0.84 (0.79–0.89) 0.86 (0.81–0.91)
Tetracycline (J01A) 1316 0.82 (0.73–0.91) 0.86 (0.77–0.96)
Beta lactam penicillin (J01C) 1734 0.87 (0.79–0.96) 0.87 (0.79–0.96)
Sulphonamides and
trimethoprim (J01E)
448 0.79 (0.66–0.96) 0.91 (0.76–1.10)
Macrolides (J01F) 360 0.69 (0.56–0.85) 0.70 (0.56–0.86)
Quinolones (J01M) 327 0.95 (0.76–1.18) 0.90 (0.72–1.12)
Nitrofurantion (J01XE) 446 0.96 (0.80–1.16) 0.85 (0.71–1.03)
Table 2. Baseline characteristics of patients with drug-treated type 2 dia-






Mean age in years (SD) 62.3 (9.4) 64.3 (10.1)
Male gender (%) 4922 (50) 2430 (49)
Mean duration of glucose-
lowering drug use in years (SD)
1.5 (2.2) 2.0 (2.2)
Mean number of antibiotics in year
prior index date (SD)
0.8 (2.5) 1.0 (3.2)
Co-medication (%)
Cardiovascular drugs 5906 (60) 3069 (62)
Antithrombotic agents 1873 (19) 1175 (24)
Systemic corticosteroids 537 (6) 382 (8)
Immunosuppressants 104 (1) 72 (2)
Antivirals 27 (0.3) 11 (0.2)
Antineoplastics 24 (0.2) 41 (0.8)
Drugs for obstructive airway
diseases
1231 (13) 713 (15)
Acid-suppressive drugs 2949 (30) 1644 (33)
k. b. pouwels et al.
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type 2 diabetes. As clinical guidelines recommend
statin treatment in almost all patients with type 2
diabetes,45,46 randomized placebo-controlled trials
evaluating the effect of statins on infections among pa-
tients with type 2 diabetes are no longer ethical. There-
fore, in the absence of evidence from randomized
trials, evidence should be obtained from observational
studies that adequately address potential (un)measured
confounding. The PSSA we applied does limit unmea-
sured confounding as we have shown in earlier studies
from our group.32–34
STRENGTH AND LIMITATIONS
An important strength of our study is that we evaluated
the association of interest using two designs that
address confounding in a different way. Despite the
differences between both designs, we obtained very
similar results, strengthening the conﬁdence in the
results. The data were obtained from a widely
researched prescription database with proven accuracy
of prescription rates among adults.30 Furthermore,
both statins and antibiotics are not available over the
counter in the Netherlands, reducing the likelihood of
misclassiﬁcation.
Our study also has some limitations. First of all,
observational studies are well known to be vulnerable
to confounding and evidence from such studies is of-
ten regarded as less important than evidence from ran-
domized controlled trials.47,48 The very similar results
obtained with both the PSSA, the unadjusted and
adjusted survival analyses suggest that the results are
not largely affected by confounding. However,
although the PSSA minimizes confounding by factors
that are stable over time, we cannot exclude confound-
ing by factors that are both associated with antibiotic
use and the timing since statin use. Besides disease
severity, which would in fact more likely bias the SR
towards an increased risk, we are not aware of any
important time-varying confounders. When the maxi-
mum time-span between both prescriptions was
lowered to 30days, the aSR became slightly lower
(0.78 vs 0.86), indicating that if time-varying
confounding would play a role, it would indeed result
in an underestimation of the effect.
A second possible limitation is exposure or outcome
misclassiﬁcation. Statin use may be misclassiﬁed as
some patients may not actually take their drug, despite
collecting the drugs from the pharmacy. This could
have resulted in an underestimation of the protective
effects of statins. Prophylactic use of antibiotics may
have had a small impact on our estimates, although a
substantial difference in prophylactic use just prior
and after statin initiation is unlikely. Some antibiotic
use may have been missed, as the database does not
capture medication dispensed during hospitaliza-
tions.30 However, a previous study that evaluated the
effect of statins on infections and that did have infor-
mation about infections treated in hospitals found even
larger protective effects,25 suggesting that antibiotic
prescribing within hospitals could not explain the pro-
tective effect. Moreover, the vast majority of antibi-
otics are prescribed in primary care,49 thereby
limiting the potential inﬂuence of antibiotics
prescribed in hospitals.
Finally, the generalizability of our ﬁndings of a
reduced risk among patients with drug-treated type 2
diabetes may be restricted to patients with diabetes.
The association between statin initiation and receiving
antibiotic prescriptions was much weaker among
patients not treated with blood-glucose lowering drugs
(aSR 0.96, 95%CI 0.93 to 0.99), consistent with the
meta-analysis of randomized trials that found no effect
on the risk of infection (RR 1.00, 95%CI 0.96–1.05).5
Unfortunately, that meta-analysis did not include sufﬁ-
cient patients with diabetes to perform subgroup
analysis.
In sensitivity analysis, we observed fairly consistent
associations across different type of antibiotics, which
suggest that the protective effect of statins may be
applicable to various types of infections. However,
these results should be interpreted with caution given
the reduced numbers per antibiotic group and the fact
that the same antibiotic can be used to treat different
infections. Nevertheless, the point estimate for
nitrofurantoin, as a proxy for urinary tract infections,
was similar to a recent study investigating the inﬂu-
ence of pravastatin on incident urinary tract infection
among adults with persistent microalbuminuria, a
condition associated with elevated Rac1 activation,50
in a randomized setting (aSR 0.85 vs HR 0.83).51
The effect against speciﬁc types of infections and the
generalizability of our ﬁndings to other high-risk
patient groups deserves further investigation.
Given the increasing concern that antimicrobial
resistance is a major threat to health care,52 additive
or alternative treatments are urgently needed. Our data,
together with experimental evidence, suggest that
statins may reduce the need for antibiotic treatment
among patients with diabetes. These ﬁndings are rele-
vant, as antibiotic pressure is an important determinant
of emergence and dissemination of antibiotic resis-
tance.52 Moreover, if it can be proven that statins
indeed reduce the risk of infections, patients with dia-
betes may have another good reason to improve their
adherence to statin treatment as infections are common
effect statins on infections among diabetics
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among patients with diabetes. Improved statin adher-
ence among patients with diabetes may reduce antibi-
otic usage, prevent cardiovascular events, and
improve the cost-effectiveness of statin treatment.
However, in the absence of randomized controlled
trials, further conformation using other confounding
minimizing designs and analytical methods is needed.
In conclusion, statin initiation was associated with a
reduced risk of receiving antibiotic prescriptions
among patients with drug-treated type 2 diabetes.
Our results support the hypothesis that statins might
be helpful in preventing infections and reduce antibi-
otic usage among this group of patients.
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